Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female ≥ 18 years of age, with body weight ≤ 160 Kg~* Diagnosis of stable CHF:~  * New York Heart Association (NYHA) functional Class II/III.~ * Receiving guideline-recommended treatment for CHF.~* Left ventricular ejection fraction \< 45%, obtained within the last 3 months prior to screening.~* NT-proBNP \> 300 ng/L in sinus rhythm or \> 900 ng/L if not in sinus rhythm (determined locally).~* Ability to exercise for at least 10 to 12 minutes based on investigator's judgment.~* Systolic BP ≥ 125 mmHg at randomization~* Renal function defined as an eGFR of ≥ 25 mL/min/1.73 m\^2 at screening (sMDRD formula).~Key Exclusion Criteria:~* Dyspnea primarily due to non-cardiac causes.~* Increased risk of developing hypotension during vasodilator therapy according to investigators judgement.~* Any contraindication for exercise testing and spirometry.~* Stopping of the spiroergometry at screening according to the stopping rules, unless the patient has reached maximum exercise capacity defined as carbon dioxide production/oxygen consumption (VCO2/VO2) \> 1.05.~* Change in guideline-recommended CHF treatment within 1 month prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Serelaxin followed by Placebo (Type: EXPERIMENTAL): On Day 1 of treatment period 1, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1-day washout, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.
- Placebo followed by Serelaxin (Type: EXPERIMENTAL): On Day 1 of treatment period 1, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1-day washout, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).